S&P 500
5.200,74 +13,07 (+0,25%) Nasdaq
16.326,05 +23,29 (+0,14%) NIKKEI 225
38.073,98 -128,39 (-0,34%) Dólar/Euro
1,0776 +0,0024 (+0,23%) Petróleo Brent
83,49 -0,09 (-0,11%) Bitcoin EUR
57.897,33 +241,77 (+0,42%)
Celltrion, Inc. (068270.KS)
Celltrion, Inc.
23 Academy-ro
Yeonsu-gu
Incheon
South Korea
82 3 2850 5000
https://www.celltrion.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Hyong-Gi Kim | CEO & Internal Director | N/A | N/A | 1965 |
| Mr. Woo-Sung Kee | CEO & Internal Director | N/A | N/A | 1961 |
| Jin-seok Seo | Co-CEO & Inside Co-Chairman of the Board | N/A | N/A | N/A |
| Mr. Stephen Yeum | Founder | N/A | N/A | N/A |
| Mr. Min-Cheol Shin | Director of Finance | N/A | N/A | 1971 |
| Mr. Ji-Hoon Choi | Director of Legal Affairs | N/A | N/A | 1971 |
Descripción
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Gobierno corporativo
El ISS Governance QualityScore de Celltrion, Inc., a día 1 de mayo de 2024, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 4; Derechos de los accionistas: 4; Compensación: 1.
